CD22 and acute lymphoblastic leukemia: To tackle these controversial treatment outcomes and anticipate the rise of new CAR T-cell modalities, this study aimed to determine the efficacy and safety of CD19, CD22, and the combination of CD19/22 CAR T-cell therapy in paediatric r/r B-ALL management using a meta-analysis approach.